Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy

PURPOSE: Regorafenib is a standard second-line treatment for hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy and safety of regorafenib in the treatment of patients with Barcelona clinic liver cancer (BCLC) stage C HCC after failure of the first-line therapy and to analyze f...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Beibei, Lu, Dong, Liu, Kaicai, Lv, Weifu, Xiao, Jingkun, Zhang, Xingming, Zhang, Zhengfeng, Chai, Jie, Wang, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940492/
https://www.ncbi.nlm.nih.gov/pubmed/36814894
http://dx.doi.org/10.2147/DDDT.S400533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940492/
https://www.ncbi.nlm.nih.gov/pubmed/36814894
http://dx.doi.org/10.2147/DDDT.S400533

Ejemplares similares